文献速递心律失常冠心病

中段心房利钠肽前体用于缺血性卒中患者房颤检测

Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究基于多中心BIOSIGNAL队列,纳入1759例急性缺血性卒中患者,在症状发作24小时内检测MR-proANP水平。结果显示MR-proANP与心源性卒中、新诊断房颤及1年内主要不良心血管事件(MACE)相关;仅含年龄和MR-proANP的模型预测新诊断房颤的AUC为0.81,校准良好,净获益优于AS5F和CHA2DS2-VASc评分。

要点

  • MR-proANP与急性缺血性卒中患者新诊断房颤风险独立相关(OR 35.3)。
  • 年龄+MR-proANP模型预测新诊断房颤AUC 0.81,可用于筛选长程心电监测人群。
  • MR-proANP与心源性卒中和1年内MACE风险相关。

核心结论

  • MR-proANP是确定急性缺血性卒中患者新诊断房颤和MACE风险的有效生物标志物,可作为筛选长程心电监测患者的决策工具。

研究设计与样本

  • 前瞻性多中心BIOSIGNAL队列研究,纳入1759例急性缺血性卒中患者,症状发作24小时内检测MR-proANP。

主要发现

  • Log10MR-proANP与心源性卒中相关(OR 7.96,95%CI 4.82-13.14;风险比3.12,95%CI 2.23-4.37)。
  • Log10MR-proANP与新诊断房颤相关(OR 35.3,95%CI 17.58-71.03;风险比11.47,95%CI 6.74-19.53)。
  • Log10MR-proANP与MACE相关(亚分布HR 2.02,95%CI 1.32-3.08)。
  • 仅含年龄和MR-proANP的模型预测新诊断房颤AUC 0.81(95%CI 0.76-0.86),校准良好(校准截距-0.086,校准斜率1.053)。

关键数值与推荐

  • 预测新诊断房颤模型净获益高于AS5F评分和CHA2DS2-VASc评分。

临床怎么用

  • MR-proANP可用于急性缺血性卒中患者新诊断房颤的风险评估,辅助筛选需长程心电监测的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Midregional pro-atrial natriuretic peptide (MR-proANP) is a promising biomarker to differentiate the underlying etiology of acute ischemic stroke (AIS). OBJECTIVES: This study aimed to determine the role of MR-proANP for classification as cardioembolic (CE) stroke, identification of newly diagnosed atrial fibrillation (NDAF), and risk assessment for major adverse cardiovascular events (MACE). METHODS: This study measured MR-proANP prospectively collected within 24 hours after symptom-onset in patients with AIS from the multicenter BIOSIGNAL (Biomarker Signature of Stroke Aetiology) cohort study. Primary outcomes were CE stroke etiology and NDAF after prolonged cardiac monitoring, as well as a composite outcome of MACE (recurrent cerebrovascular events, myocardial infarction, or cardiovascular death) within 1 year. Logistic/Poisson and subproportional hazard regression were applied to evaluate the association between MR-proANP levels and outcomes. Additionally, a model for prediction of NDAF was derived and validated as a decision tool for immediate clinical application. RESULTS: Between October 1, 2014, and October 31, 2017, this study recruited 1,759 patients. Log10MR-proANP levels were associated with CE stroke (OR: 7.96; 95% CI: 4.82-13.14; risk ratio: 3.12; 95% CI: 2.23-4.37), as well as NDAF (OR: 35.3; 95% CI: 17.58-71.03; risk ratio: 11.47; 95% CI: 6.74-19.53), and MACE (subdistributional HR: 2.02; 95% CI: 1.32-3.08) during follow-up. The model to predict NDAF including only age and MR-proANP levels had a good discriminatory capacity with an area under the curve of 0.81 (95% CI: 0.76-0.86), was well calibrated (calibration in the large: -0.086; calibration slope 1.053), and yielded higher net-benefit compared with validated scores to predict NDAF (AS5F score, CHA2DS2-VASc [Congestive Heart Failure, Hypertension, Age ≥65 or ≥75, Diabetes, Prior Cardioembolic Event, (female) Sex, or Vascular Disease] score). CONCLUSIONS: MR-proANP is a valid biomarker to determine risk of NDAF and MACE in patients with AIS and can be used as a decision tool to identify patients for prolonged cardiac monitoring. (Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL study [BIOSIGNAL]; NCT02274727).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Schweizer, Arnold, König, et al. Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke. J Am Coll Cardiol. 2022. PMID: 35393018. doi:10.1016/j.jacc.2022.01.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。